In Canada, sales of non-steroid anti-inflammatory and antirheumatic drugs are projected to decrease gradually in US Dollars PPP per capita from 2024 to 2028, starting at 6.2 in 2024 and declining to 6 in 2028. The forecast shows a stable market in the initial years followed by a minor decrease.
Trends to watch for include potential innovation in drug formulations, changes in regulations affecting drug pricing, and shifts in healthcare policies that may influence market dynamics. Additionally, demographic changes such as an aging population may impact demand for anti-inflammatory and antirheumatic medications.
